[1]Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61: 69-90.
[2]程树群, 李 楠, 吴孟超. 门静脉癌栓分型与治疗选择[J]. 中国普外基础与临床杂志, 2012, 19: 240-242.
[3]Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma[J]. Surg Oncol Clin N Am 2003, 12: 25-34.
[4]Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma[J]. CA Cancer J Clin, 2012, 62: 394-399.
[5]Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379: 1245-1255.
[6]Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56: 908-943.
[7]中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治的专家共识[J]. 中华医学信息导报, 2009, 24: 22-23.
[8]Thanos L, Sotiropoulou E, Tanteles S, et al. Direct radiofrequency ablation of portal vein tumor thrombus in continuity with hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2010, 21: 285-288.
[9]Giorgio A, Di Sarno A, De Stefano G, et al. Hepatocellular carcinoma with cirrhosis: are patients with neoplastic main portal vein invasion eligible for percutaneous radiofrequency ablation of both the nodule and the portal venous tumor thrombus?[J]. AJR Am J Roentgenol, 2009, 193: 948-954.
[10]葛乃建, 杨业发, 申淑群, 等. 经皮穿刺射频消融治疗门静脉癌栓15例[J]. 介入放射学杂志, 2014, 23: 883-886.